387 U.S. 136 (1967)
In 1962 Congress amended the Federal Food, Drug, and Cosmetic Act to require manufacturers of prescription drugs to print the established name of the drug prominently and in type at least half as large as that used for any proprietary name on labels and other printed material.1 The underlying purpose was to inform doctors and patients that many drugs sold under trade names are identical to those sold under established names at lower prices.2
The Commissioner of Food and Drugs published proposed regulations in the Federal Register after receiving delegated authority, invited and considered comments from interested parties, and promulgated a regulation requiring that the established name accompany each appearance of the proprietary name on labels and in advertisements for prescription drugs, with a similar rule for advertisements.3
Thirty-seven individual drug manufacturers and the Pharmaceutical Manufacturers Association, whose members manufacture more than ninety percent of the nation's prescription drugs, brought suit in district court challenging the regulations on the ground that the Commissioner exceeded his statutory authority by imposing an every-time requirement.4
The District Court granted declaratory and injunctive relief on cross-motions for summary judgment, but the Court of Appeals for the Third Circuit reversed without reaching the merits, holding that pre-enforcement review was unauthorized and that no actual case or controversy existed.5 The Supreme Court granted certiorari because of the general importance of the question and an apparent conflict with a decision of the Second Circuit.6
The regulations were promulgated after formal notice-and-comment procedures, were made effective upon publication in the Federal Register, and carried an agency expectation of immediate compliance.7 Petitioners alleged that compliance would require extensive and costly changes to all labels, advertisements, and promotional materials while noncompliance would expose them to serious criminal and civil penalties.8
Whether the Federal Food, Drug, and Cosmetic Act precludes pre-enforcement judicial review of regulations promulgated by the Commissioner of Food and Drugs?9
No. The Federal Food, Drug, and Cosmetic Act does not preclude pre-enforcement review of the Commissioner's regulations.12 The specific review procedures in section 701(f) were intended to provide an additional remedy for technical factual determinations rather than to bar traditional equity or declaratory judgment actions.13 This is confirmed by the saving clause in section 701(f)(6) and legislative history showing no intent to eliminate other remedies.14 The regulations were promulgated after formal notice-and-comment procedures and constitute final agency action subject to review.
The Federal Food, Drug, and Cosmetic Act does not preclude this pre-enforcement action.15
Whether the regulations present a justiciable case or controversy suitable for declaratory and injunctive relief under the Administrative Procedure Act and Declaratory Judgment Act?16
Declaratory and injunctive relief under the Administrative Procedure Act and Declaratory Judgment Act is available for final agency action that creates a concrete dispute with immediate effects on the challenging parties.17
Yes. The regulations present a justiciable case or controversy. They impose an authoritative interpretation with direct and immediate effects on the day-to-day business of the petitioners. This places them in the precise dilemma the Declaratory Judgment Act was designed to address. The petitioners, representing manufacturers of more than ninety percent of the nation's prescription drugs, must either incur extensive compliance costs or risk serious criminal and civil penalties for noncompliance.18
The regulations present a justiciable case or controversy suitable for declaratory and injunctive relief.19
Whether the issues raised are ripe for judicial resolution in light of their fitness for decision and the hardship to the parties of withholding review?20
Ripeness doctrine requires evaluation of both the fitness of the issues for judicial decision and the hardship to the parties of withholding court consideration.21 Fitness turns on whether the issue is purely legal and the agency action is final.22 Hardship arises when a regulation requires an immediate and significant change in conduct with serious penalties attached to noncompliance.23
Yes. The issues are ripe for judicial resolution because the question presented is purely legal.24 The regulations constitute final agency action promulgated after notice and comment and made effective upon publication.25 The petitioners face immediate hardship in the form of costly changes to all labels, advertisements, and promotional materials or exposure to serious sanctions.26 The agency expected immediate compliance and the regulations have a direct effect on the petitioners' business operations.27
The issues raised are ripe for judicial resolution.28